Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glioma
is a lethal central nervous system tumor with poor patient survival prognosis. Because of the molecular heterogeneity, it is a challenge to precisely determine the type of the tumor and to choose the most effective treatment. Therefore, novel biomarkers are essential to improve the diagnosis and prognosis of
glioma
tumors. Class 3 semaphorin proteins (SEMA3) play an important role in tumor biology. SEMA3 transduce their signals by using neuropilin and plexin receptors, which functionally interact with the vascular endothelial growth factor-mediated signaling pathways. Therefore, the aim of this study was to explore the potential of SEMA3 signaling molecules for prognosis of
glioma
patient survival. The quantitative real-time PCR method was used to evaluate mRNA expression of
SEMA3(A-G)
, neuropilins (
NRP1
and
NRP2
), plexins (
PLXNA2
and
PLXND1
), cadherins (
CDH1
and
CDH2
), integrins (
ITGB1, ITGB3, ITGA5,
and
ITGAV
),
VEGFA
and
KDR
genes in 59 II-IV grade
glioma
tissues. Seven genes significantly associated with patient overall survival were used for multi-biomarker construction, which showed 64%, 75%, and 68% of accuracy of predicting the survival of 1-, 2-, and 3-year
glioma
patients, respectively. The results suggest that the seven-gene signature could serve as a novel multi-biomarker for more accurate prognosis of a
glioma
patient's outcome.
...
PMID:A SEMA3 Signaling Pathway-Based Multi-Biomarker for Prediction of Glioma Patient Survival. 3303 21
